Founded in May 2017 and based at the Babraham Research Campus in Cambridge, PredictImmune develops pioneering tools for guiding treatment options in immune-mediated inflammatory diseases like Crohn’s and ulcerative colitis (IBD).
Based on ten years of research at Cambridge University, PredictImmune’s test kits help both clinicians and patients to understand, at the point of diagnosis, the likely course of disease and opens the possibility of better treatment choices from the outset.
Business funding insights
Business matters: Reflecting on where next for dealmakers
Reflecting on what it all means for the investors that back companies – the community which BGF is part of.
Businesses need an equity solution to the economic fallout from the crisis
We’re all aware of the devastating impact the coronavirus pandemic has had on both British lives and businesses. But the…